About this article Cite this article Jensen, A.B., Renstrm, F., Aczl, S
The hierarchy based on current clinical data places tirzepatide at the top (20.2% average loss), followed by semaglutide (13.7% average loss), then liraglutide (approximately 8% average loss)
Tirzepatide has shown similar results: in a phase 2 trial, up to 73.3% of participants at the highest dose achieved MASH resolution without worsening fibrosis at 52 weeks, compared to 13.2% on placebo
Therefore, 10 g/mL A-CDs or AA-CDs was selected for further experiments
It lower blood pressure and improve cholesterol profiles in many users
Fat is distributed throughout your body, but one place where its especially dangerous is your abdomen